Monoclonal antibody treatment for COVID-19, like the one from Regeneron, isn’t a traditional drug. It’s tough to make in the lab.
Source: The Daily News
Why monoclonal antibodies are expensive and hard to make in the fight against COVID-19.
Published in Lascassas
More from LascassasMore posts in Lascassas »
- Tennessee's special session reignited the school safety debate. But what's actually best?
- Can't wait to see fall foliage at its peak? These Nashville-area hikes are the best to see leaves change color
- 2023-2024 Best high schools rankings are out and three Nashville-area schools made the top 100
- Scientists access ORNL's supercomputer from all over: New York, a plane, even Hardee's
- TN special session live updates: As House, Senate end special session, chaos ensues
Be First to Comment